doxepin
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
218
Go to page
1
2
3
4
5
6
7
8
9
December 04, 2025
Doxepin and Mirtazapine Use in Children and Adolescents With Symptoms of Insomnia - A Single-Center Retrospective Review.
(PubMed, Pediatr Neurol)
- "We found both doxepin and mirtazapine as effective and tolerable treatments options in improving subjective sleep onset and maintenance issues in children with insomnia."
Journal • Retrospective data • CNS Disorders • Insomnia • Pediatrics • Sleep Disorder
November 29, 2025
Targeted interventions to promote sleep for hospitalized older adults: a narrative review.
(PubMed, Hosp Pract (1995))
- "Sleep promotion should include, at a minimum, non-pharmacological interventions (e.g. increasing familiarity, reducing sensory stimulation as bedtime approaches, maintaining environmental and behavioral zeitgebers). Pharmacological (e.g. ramelteon, trazadone, doxepin, dual orexin receptor antagonists) and nutraceutical (e.g. melatonin, magnesium) interventions may be appropriate, Certain pharmacological options are considered potentially unsafe for older adults (e.g. benzodiazepines, Z-drugs, antihistamines) and should be avoided in this population."
Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia
December 01, 2025
Undiagnosed Delusional Infestation Leading to Severe Self-Inflicted Injuries: A Case Report.
(PubMed, Case Rep Psychiatry)
- "Treatment with low-dose risperidone and doxepin was initiated following empathic, nonconfrontational engagement...This case highlights the risk of severe self-injury in DI and underscores the need for timely psychiatric evaluation and a compassionate, collaborative approach. Reframing treatment goals to prioritize symptom relief over delusional challenge may enhance engagement and facilitate recovery."
Journal • Dermatology • Pruritus • Psychiatry • Thermal Injury
November 22, 2025
The use of antihistamine and antihistamine-like drugs for cancer-related pain: a narrative review.
(PubMed, Support Care Cancer)
- "Analysis of these studies demonstrated meaningful evidence that antihistamine and antihistamine-like drugs may offer some benefit for treating cancer-related pain."
Journal • Review • Mucositis • Oncology • Pain • Peripheral Neuropathic Pain • Stomatitis
November 19, 2025
Sleep-promoting effects and mechanisms of Bacillus coagulans IDCC 1201: evidence from pentobarbital-induced sleep and electroencephalography analysis in mice.
(PubMed, Food Funct)
- "Delta activity analysis indicated no adverse effects on sleep quality. These findings suggest that B. coagulans IDCC 1201 enhances sleep by modulating the GABAergic system and improving sleep architecture, highlighting its potential as a functional ingredient for sleep enhancement without the drawbacks of conventional sleep aids."
Journal • Preclinical • CNS Disorders • Infectious Disease
November 12, 2025
The Pharmacist's Role in Age-Friendly Mobility.
(PubMed, Sr Care Pharm)
- "Instead of doxepin, a highly anticholinergic antidepressant, the resident is effectively transitioned to escitalopram, resulting in a stable mood...Although the resident primarily presented with mobility issues, her case illustrates the interplay of all 4Ms and underscores the importance of a collaborative approach. This patient, whose main concern was mobility, required interventions to optimize medications and address mentation through the treatment of depression, all while maintaining a focus on what matters most to her as an individual."
Journal • Cardiovascular • CNS Disorders • Depression • Diabetes • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Psychiatry • Rheumatology • Type 2 Diabetes Mellitus
November 07, 2025
Repurposed doxepin targeting host AXL kinase to disrupt viral 2C-mediated immune evasion in Coxsackievirus B infection.
(PubMed, Antiviral Res)
- "Furthermore, our findings unveiled a novel immune evasion mechanism employed by CVB, wherein AXL kinase modulates viral replication by regulating host immune signaling. These results highlight AXL as a critical host factor in CVB infection and provide a strong rationale for considering DH as a potential host-targeted therapeutic strategy for CVB-associated diseases, particularly in the absence of specific antiviral agents."
Journal • Cardiovascular • CNS Disorders • Infectious Disease • Inflammation • AXL • IL1B • IL6
November 03, 2025
A double layer oral film loaded with doxepin hydrochloride for the treatment of chemotherapy-induced oral mucositis.
(PubMed, Front Pharmacol)
- "Further investigation revealed that the healing mechanism involves the alleviation of oxidative stress and attenuation of excessive inflammatory responses. The doxepin hydrochloride patch developed in this study provides a novel pharmaceutical option for clinical management of CIOM."
Journal • Mucositis • Oncology • Pain • Stomatitis
October 27, 2025
The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
(PubMed, Lancet)
- "We found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters. Treatment guidelines should be updated to reflect differences in physiological risk, but choice of antidepressant should be made on an individual basis, considering clinical presentation and preferences of patients, carers, and clinicians."
Journal • Retrospective data • CNS Disorders • Mental Retardation • Metabolic Disorders • Psychiatry
October 22, 2025
Psychological Adverse Events and Associated Safety Profiles of Doxepin: A Pharmacovigilance Study Using VigiBase.
(PubMed, J Korean Med Sci)
- "Although no definitive safety signals were detected in our AESI analyses, we identified safety signal for drug abuse. Clinicians should carefully weigh the risks and benefits when prescribing doxepin and emphasize the need for vigilant monitoring of AEs."
Adverse events • Journal • CNS Disorders • Depression • Insomnia • Psychiatry • Sleep Disorder
October 17, 2025
Efficacy and safety of insomnia pharmacotherapies: Convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis.
(PubMed, Sleep Med)
- "Comprehensively considering the efficacy effect size, time windows (follow-up period, age, and types of insomnia), PV, severity of imperative adverse events, we propose prioritizing the use of daridorexant 25 mg/d for insomnia characterized by difficulty maintaining sleep and insufficient sleep duration. For insomnia characterized by difficulty falling asleep, we recommend prioritizing the use of lemborexant 10 mg/day or zolpidem 10 mg/day. For overall poor sleep efficiency, we recommend using lemborexant. Drug selection should be based on the types of insomnia and drug safety. More head-to-head clinical trials are needed to confirm those findings."
Journal • Review • CNS Disorders • Insomnia • Pulmonary Disease • Sleep Disorder
July 24, 2025
Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis.
(PubMed, Front Psychiatry)
- "Compared with placebo, zolpidem (somnolence: relative risk [RR] 1.85; dizziness: RR 2.33; headache: RR 1.26), zopiclone (somnolence: RR 2.02; dizziness: RR 2.33; dysgeusia: RR 7.84), indiplon (somnolence: RR 3.46; dizziness: RR 2.30; headache: RR 1.63), gaboxadol (dizziness: RR 3.44), eszopiclone (somnolence: RR 2.00; dizziness: RR 3.18; dysgeusia: RR 10.54), estazolam (somnolence: RR 2.08), flunitrazepam (somnolence: RR 3.04), flurazepam (somnolence: RR 2.52), lemborexant (somnolence: RR 6.57), nitrazepam (somnolence: RR 3.80), Ramelteon (somnolence: RR 2.19), suvorexant (somnolence: RR 3.32), Temazepam (somnolence: RR 3.77), trazodone (somnolence: RR 2.86), triazolam (somnolence: RR 2.35), and esmirtazapine (somnolence: RR 4.63; dizziness: RR 2.87) had the most harmful profile in nervous system disorders...Data on some drugs like flurazepam, nitrazepam, triazolam, and zaleplon in some outcomes were mainly based on limited study with rare event and thus was highly..."
Adverse events • Journal • Retrospective data • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Insomnia • Otorhinolaryngology • Pain • Psychiatry • Respiratory Diseases • Sinusitis • Sleep Disorder • Xerostomia
July 22, 2025
Sulfonatocalixarene Promotes Drug Assembly Based on Supramolecular Host•-Guest Complexation in Aqueous Solution.
(PubMed, Chem Asian J)
- "Supramolecular nano-sized assemblies with high structural stability are designed based on hostguest complexation in aqueous solution using sulfonatocalix[n]arenes (SXCn) as macrocyclic hosts and three drug molecules (doxepin, desipramine, and promazine)...Despite the high-water solubility of SCX4 and the drug molecules, their combination reveals the formation of supramolecular assembly at low millimolar concentrations. These assemblies exhibit a thermoresponsive behavior, highlighting their potential for the design of functional materials."
Journal
June 20, 2025
Pharmacotherapy of psychiatric inpatients with mental and behavioral disorders caused by sedatives or hypnotics (F13): Results from an observational pharmacovigilance program between 2000 and 2017.
(PubMed, Addict Sci Clin Pract)
- "We found high rates of non-SHA drugs among patients treated for SHA-SUD. The prevalent use of psychotropic drugs with strong sedating properties indicates a symptom-oriented treatment approach, which is often "off-label" but may be clinically necessary. Main limitation is the cross-sectional design of the AMSP databank. Therefore, we cannot provide any follow up data on the patient collective especially regarding outcome."
Adverse events • Journal • Addiction (Opioid and Alcohol) • Behavior Disorders • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry
June 10, 2025
Design strategies for titanium surfaces to adsorb and release drugs: An in vitro study.
(PubMed, Biomed Mater Eng)
- "The results suggest that a rougher or ionically charged surface does not guarantee drug adsorption. In contrast, the use of a transport vehicle such as a polyvinyl coating ensures the release of the drug, initiating its therapeutic effect within the first minutes, and maintained for a period of between 120 and 180 min."
Journal • Preclinical • Inflammation • Pain
April 27, 2025
Carbon Materials in Voltammetry: An Overview of Versatile Platforms for Antidepressant Drug Detection.
(PubMed, Micromachines (Basel))
- "Moreover, the combination of voltammetric approaches with the unique characteristics of carbon and its derivatives has led to the development of powerful electrochemical sensing tools for detecting antidepressant drugs, which are highly desirable in healthcare, environmental monitoring, and the pharmaceutical industry. In this review, carbon-based materials, such as glassy carbon and boron-doped diamond, and a wide spectrum of carbon nanoparticles, including graphene, graphene oxides, reduced graphene oxides, single-walled carbon nanotubes, and multi-walled carbon nanotubes were described in terms of the sensing performance of agomelatine, alprazolam, amitriptyline, aripiprazole, carbamazepine, citalopram, clomipramine, clozapine, clonazepam, desipramine, desvenlafaxine, doxepin, duloxetine, flunitrazepam, fluoxetine, fluvoxamine, imipramine, nifedipine, olanzapine, opipramol, paroxetine, quetiapine, serotonin, sertraline, sulpiride, thioridazine, trazodone, venlafaxine,..."
Journal • Review • CNS Disorders • Depression • Mood Disorders • Personality Disorder • Psychiatry
April 15, 2025
The effect of doxepin 3 mg on sleep latency: a pooled analysis of two phase 3 trials.
(PubMed, Sleep Breath)
- "Doxepin 3 mg has a statistically significant effect on sleep latency on the first night of treatment in adults with insomnia that did not reach the clinical significance threshold."
Clinical • Journal • P3 data • Retrospective data • CNS Disorders • Insomnia • Sleep Disorder
April 14, 2025
Trazodone versus doxepin as a pharmacologic sleep aid in psychiatric inpatients: A retrospective cohort study.
(PubMed, Ment Health Clin)
- "After treatment failure with trazodone 50 mg, there was no statistically significant difference in efficacy or tolerability between trazodone 100 mg and doxepin 25 mg for insomnia. A prospective trial would be necessary to directly compare the 2 treatment options."
Journal • Retrospective data • CNS Disorders • Insomnia • Psychiatry • Sleep Disorder
April 11, 2025
High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of 23 antidepressants and active metabolites in human serum and its application in therapeutic drug monitoring.
(PubMed, Front Pharmacol)
- "In this paper, we developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to study simultaneously TDM and clinical pharmacokinetics of 23 antidepressants and active metabolites: sertraline, escitalopram, fluvoxamine, paroxetine, duloxetine, milnacipran, fluoxetine, venlafaxine, O-desmethylvenlafaxine, mirtazapine, trazodone, bupropion, hydroxybupropione, norfluoxetine, vortioxetine, agomelatine, mianserin, doxepine, desmethyldoxepin, clomipramine, desmethylclomipramine, amitriptyline and nortriptyline hydrochloride...Validation of the developed method was carried out based on the Chinese Pharmacopoeia guidelines for bioanalytical method validation, including assessment of specificity, calibration curves, carryover, accuracy, crosstalk, precision, stability, recovery, dilution integrity and matrix effect. The results showed that a simple, fast, reliable and specific HPLC'MS/MS method was developed and validated, and all the..."
Journal • CNS Disorders • Depression • Psychiatry
April 01, 2025
Circadian antidepressant treatments in depression: A systematic review and meta-analysis.
(PubMed, Chronobiol Int)
- "The optimal time of maximum efficacies in 5 out of 15 drugs in the 10 studies was at zeitgeber time (ZT) 2, including fluoxetine, sertraline, citalopram, doxepin, and agomelatine. The best therapeutic effects of mirtazapine, trazodone, and agomelatine were at ZT10, while maximum efficacies of venlafaxine and fluvoxamine were at ZT6 and ZT13, respectively...More prospective randomized trials or randomized experiments are demanded to establish recommendations for optimal circadian timing of depression based on zeitgeber time. It would be of interest to further evaluate this time-selection as a potential viable novel therapeutic in future research."
Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry
March 13, 2025
Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity.
(PubMed, Molecules)
- "In addition, there is a serious problem of increasing resistance of microorganisms to antibiotics. In this article, we found that almost all of the antidepressants considered (except moclobemide, haloperidol, and doxepin) have antimicrobial activity and can suppress the growth of not only pathogenic microorganisms but also the growth of bacteria that directly affect mental health (such as Lactobacillus, Lactococcus, Streptococcus, Enterococcus, and Bifidobacterium)."
Journal • Review
February 12, 2025
Incidence and Predictors of Long-term Hypnotic Receipt among Patients with Chronic Obstructive Pulmonary Disease.
(PubMed, Ann Am Thorac Soc)
- "Despite guideline recommendations, long-term hypnotic receipt is common among patients with COPD. Future work to prevent long-term hypnotic prescriptions should consider the role that respiratory symptoms and mental health comorbidities may have in driving this practice."
Journal • Chronic Obstructive Pulmonary Disease • CNS Disorders • Depression • Immunology • Insomnia • Major Depressive Disorder • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Pulmonary Disease • Respiratory Diseases • Sleep Disorder
February 03, 2025
Psychotropic Drugs in Dermatology Part 1: Anti-depressants and Mood Stabilisers.
(PubMed, Indian J Dermatol)
- "These include selective serotonin reuptake inhibitors like citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, alongside selective serotonin norepinephrine reuptake inhibitors such as venlafaxine, desvenlafaxine, and duloxetine. Additionally, norepinephrine dopamine reuptake inhibitors like bupropion; tricyclic antidepressants including doxepin, amitriptyline, imipramine, and clomipramine; and tetracyclic antidepressants like mirtazapine are commonly employed. Supplementary medications like anti-convulsants (e.g., gabapentin and pregabalin) further enrich the therapeutic landscape in psycho-dermatology...After screening 2287 records, 26 studies met the inclusion criteria. The findings underscore the potential role of psychotropic drugs in managing dermatological conditions, highlighting the need for further research to strengthen the evidence base in psycho-dermatology."
Journal • Review • CNS Disorders • Dermatology • Mental Retardation • Psychiatry
January 28, 2025
Addressing Sleep Disorders in Psychiatry: Comparing the Use of Melatonin, Trazodone, and Doxepin.
(PubMed, Cureus)
- "Conclusion In psychiatric patients, trazodone was the most successful medication for enhancing sleep quality; however, other groups cannot use it due to its adverse effects. For patients who were more likely to have side effects, melatonin was a safer option, but doxepin offered a good balance between effectiveness and tolerability."
Journal • CNS Disorders • Hypotension • Psychiatry • Sleep Disorder • Xerostomia
January 28, 2025
Insights into prescribing patterns for antidepressants: an evidence-based analysis.
(PubMed, BMC Med Inform Decis Mak)
- "Our findings provide valuable insights into the nuanced factors that shape evidence-based antidepressant prescribing practices, offering a foundation for more personalized, effective depression treatment. Further research is needed to validate these models in other extant databases. These findings contribute to a more comprehensive understanding of antidepressant prescribing practices and have the potential to improve patient outcomes in the management of depression."
Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Insomnia • Nicotine Addiction • Pain • Psychiatry • Sleep Disorder • Tobacco Addiction
1 to 25
Of
218
Go to page
1
2
3
4
5
6
7
8
9